Blogs for August 2017

Atherosclerosis Disease Progression Cell Markers

Tuesday, August 29, 2017 - 14:56
Can Caner Immunotherapy Principles Be Applied to Neurodegenerative Diseases?

R&D Systems Cell Marker Pages: The Easiest Way to Plan Your Next Experiment

One of the challenges of moving into a new research field or expanding your current field of study is determining the best markers to identify the cells you want. R&D Systems has been providing researchers with reliable tools for defining cell populations for over 30 years. Now we’ve added new Cell Marker Tools for Atherosclerosis, Asthma, and...

A Role for VSIG-3/VISTA Signaling in Acquired Resistance to Anti-PD-1 Therapy?

Wednesday, August 23, 2017 - 09:33
t-cell and tumor cell

Immunotherapy has revolutionized the way we treat cancer. Ground breaking studies have demonstrated that co-signaling molecules such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death 1 (PD-1) receptor, and programmed death ligand 1 (PD-L1) are an important therapeutic targets. However, these victories have been tempered by the development of acquired resistance in some cases. Why is this happening? What are the mechanisms of acquired resistance to immune checkpoint blockade?


R&D Systems Develops A Highly Sensitive and Specific Assay to Detect Anti-Zika Virus IgG

Tuesday, August 22, 2017 - 12:16
zika mosquito

Zika virus (ZIKV) is a mosquito-borne, single-stranded, positive-sense RNA virus belonging to the Flaviviridae family. It is closely related to other members of the Flavivirus genus including dengue virus, West Nile virus, yellow fever virus, tick-borne encephalitis virus, and Japanese encephalitis virus. ZIKV was first isolated from a rhesus monkey in Uganda in 1947 and the first human cases were detected in the 1950s in Uganda, Tanzania, and Nigeria. Since that time, there have been significant outbreaks in Africa, Southeast Asia, and the Pacific Islands, but the...

Bio-Techne Go Everywhere Travel Grant - July Recipient Selected!

Wednesday, August 16, 2017 - 13:52
Bio-Techne travel grants

July 2017 Go Everywhere with Bio-Techne Travel Grant Awarded to PhD Student from the University of Lisbon!

Bio-Techne launched its Go Everywhere Travel Grant Program which awards $1000 USD (or equivalent) to 1 researcher each month to attend the meeting of their choice. This grant program allows the researcher to attend more targeted meetings in their field and provides funding to support both small and large scientific associations that promote discovery and collaboration.

The recipient of the July 2017 grant is Pedro Papotto, a PhD Student at the Institute of Molecular Medicine at the University of Lisbon in Portugal!


The Latest Advances in Inflammation Research from WCI2017

Monday, August 14, 2017 - 07:22
EMEA Immunology Conference

The Latest Advances in Inflammation Research from WCI 2017

The World Congress on Inflammation (WCI 2017) is a prestigious biennial international conference that brings together scientists from around the world to discuss the latest developments in inflammation research. Bio-Techne attended this year’s exciting Congress from July 8th-12th organized by the British Inflammation Research Association (BIRAs). The plenary lectures were presented by leading researchers on topics ranging from inflammation in aging, neuroinflammation, innate immune memory, regulation of inflammation, microbiome and inflammatory bowel disease. Here are some highlights that we discovered from the meeting....

Travel Grant Recipients to Neuroscience 2017 Announced

Monday, August 7, 2017 - 12:58
Bio-Techne travel grants

The Society for Neuroscience Annual Meeting is the largest scientific conference for neuroscientists in the world. This year, approximately 30,000 researchers will gather in Washington D.C. from November 11-15, 2017 to share their work, learn new ways...

Can Cancer Immunotherapy Principles Be Applied to Neurodegenerative Diseases?

Monday, August 7, 2017 - 09:18
Can Caner Immunotherapy Principles Be Applied to Neurodegenerative Diseases?

Alzheimer's disease, a progressive, neurodegenerative disease of the central nervous system, is the most common form of dementia. It is estimated that 44 million people worldwide have Alzheimer’s disease or a related dementia. Alzheimer’s disease has proved difficult to treat, mainly because the symptoms of the disease only emerge years after disease onset. The treatments that are currently available for Alzheimer’s disease only help to ease the symptoms of the disease; they do not slow or stop its progression. The goal of Alzheimer’s disease research is to develop effective therapies that stop or prevent the underlying cause of the disease.

In a recent edition of...

Quarterly Protein Product and Data Update: Edition #2

Thursday, August 3, 2017 - 14:27
Protein Structure Banner

New Products

anti-zika virus igg elisa
New! Human Anti-Zika Virus IgG ELISA Kit
R&D Systems now offers an Anti-Zika Virus IgG ELISA to measure anti-Zika virus (ZIKV) IgG antibodies in human serum. In-house testing shows that R&D Systems® assay is more specific and...

Stem Cells in the News - August 2017

Tuesday, August 1, 2017 - 10:16
Stem Cells in the News

We have captured this month's most interesting, innovative, and maybe some of the strangest examples of stem cells in the news from around the world.


In July, the countries of Germany and Poland announced the Dioscuri Programme, which will fund research efforts across Western and Eastern Europe. This program will provide funding for ten...